Takeda completes the evaluation of RaQualia's compound
RaQualia Pharma Inc. ("RaQualia") announced that under the agreement with Takeda Pharmaceutical Company Limited ("Takeda"), Takeda has completed their evaluation of the effectiveness of a RaQualia compound targeting a non-disclosed indication in the gastroenterology therapeutic area.
After completion of this evaluation Takeda has decided to not pursue further development of the compound. Upon this decision, RaQualia will receive all data that Takeda generated during the evaluation.
RaQualia remains confident in the potential medical use of this class of compounds and will continue to pursue such possibilities and explore potential partnerships.
The financial forecasts for FY2018 (January 1, 2018 to December 31, 2018) will not be affected by this announcement.
####